Original news and analysis on international IP policy
A new report launched in time for this week's AIDS conference in South Africa analyzes factors relating to access to HIV/AIDS treatments over the past 15 years. The analysis includes a look at government policies used during that time, the contribution of generic and research-based industries, and the importance of voluntary licensing.
Worldwide sales for orphan drugs are forecast to reach $178 billion by 2020, according to a recent industry report. Moreover, the orphan drug market is expected to grow almost 12 percent per year, a level the broader pharmaceutical market “could only dream about” with its expected annual growth of 5.9 percent, according to Lisa Urquhart, editor of EvaluatePharma Vantage.
A bill introduced in Kenya’s parliament intended to streamline, govern and regulate the country’s information and communications technology (ICT) sector has been met with opposition from different quarters over fears that it could put ICT technicians out of practice and stifle the country’s innovation capacity if passed into law.
BARCELONA, Spain -- The Huawei v ZTE Case C - 170/13, 21 July 2015 prescribed some guidelines for fair, reasonable and non-discriminatory (FRAND) licensing negotiations, for both standard-essential patent holders and users. A recent private-sector panel addressed European FRAND case law and the latest information and communications technology industry policy opinions, in particular concerning royalty assessment rate (end-user or technology), royalty stacking, patent pool approach and injunctions.
BARCELONA, Spain -- A recent industry conference panel here covered topics of changing intellectual property scenarios perceived from different angles, in particular from operating companies which manufacture products or services and patent assertion entities (PAEs).
Populism is in vogue these days and critics of pharmaceutical patents are trying to ride the wave, claiming that undermining patents will dramatically decrease prices but not reduce innovation. Both sides of that claim are flawed, writes Steven Tepp.
With the aim of strengthening regional cooperation in intellectual property, the four member states of the Visegrad Group, which comprises Poland, Hungary, the Czech Republic and Slovakia, launched the Visegrad Patent Institute (VPI) on 1 July. Applicants will be allowed to communicate with the institutions in their respective mother tongues, and fees for Patent Cooperation Treaty (PCT) applications will be reduced by as much as 40 percent, according to Poland’s Patent Office (UPRP).
World Health Organization member states have until 15 July to submit views on a five-year-old mechanism allowing for swifter sharing of pandemic influenza viruses and benefit-sharing measures, according to the group tasked with providing a report on the review.
What do global innovators make of India’s new National Intellectual Property Rights Policy? A recent discussion on “India’s National IPR Strategy: A View from Global Innovators” in Washington DC attempted to assess the opportunities and challenges ahead from the perspective of American companies.
The Netherlands’ Presidency of the European Council proved to be far from quiet in relation to pharmaceutical affairs. June 17 was the concluding Health Ministers Council (EPSCO) that signed off the most strongly-worded conclusions Brussels observers can recall. The meeting signaled the end of an overall successful and impactful Presidency in the highly sensitive field of medicines. The past semester has been eventful to say the least.